全球抗生素抗药性市场规模、份额、趋势和成长分析报告（2026-2034年）

预计抗生素抗药性市场将从 2025 年的 103.7 亿美元成长到 2034 年的 172.7 亿美元，2026 年至 2034 年的复合年增长率为 5.83%。

随着全球抗生素抗药性问题日益凸显，成为最严峻的公共卫生挑战之一，全球抗生素抗药性市场也备受关注。医疗保健和农业领域抗生素的过度使用和滥用正在加速抗药性细菌的产生，使感染疾病的治疗更加困难。在医疗系统努力对抗抗药性病原体的同时，全球市场对创新诊断工具、替代疗法和新型抗生素的需求也显着成长。

成长要素包括人们对抗生素抗药性的认识不断提高、政府主导的遏制抗生素滥用的倡议增多，以及对新型抗生素研发投入的增加。医疗机构也正致力于推行合理使用抗生素的方案，以促进负责任的抗生素使用。此外，快速诊断技术的进步使临床医生能够更有效地识别抗药性感染疾病，从而实现更有针对性的治疗，并减少不必要的抗生素处方。

全球抗生素抗药性市场前景受各国政府、製药公司和研究机构之间的国际合作影响。对生物技术和创新药物研发平台的投资有望加速下一代抗菌治疗方法的开发。此外，旨在加强监测系统和改进感染控制方法的国际努力也可能促进市场成长。由于抗菌素抗药性仍然是全球性的健康威胁，应对这项挑战的解决方案市场预计将稳步扩大。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球抗生素抗药性市场：依疾病分类

• 市场分析、洞察与预测
• 复杂性尿道感染(cUTI)
• CDI（困难梭状桿菌感染疾病）
• 急性细菌性胃及结构感染疾病（ABSSSI）
• 本院获得性细菌性肺炎（HABP）
• 社区型肺炎 (CABP)
• cIAI（复杂性腹腔内感染疾病）
• 血流感染疾病（BSI）

第五章：全球抗生素抗药性市场：以病原体划分

• 市场分析、洞察与预测
• 大肠桿菌
• 肺炎克雷伯菌
• 铜绿假单胞菌
• 金黄色葡萄球菌
• 鲍曼鲍氏不动桿菌
• 肺炎球菌
• 流感嗜血桿菌
• 困难梭状芽孢桿菌
• 粪肠球菌

第六章：全球抗生素抗药性市场：依药物类别划分

• 市场分析、洞察与预测
• Oxazolidinone系列
• 醣肽
• 四环霉素
• 联合治疗
• 头孢菌素
• 其他的

第七章：全球抗生素抗药性市场：依作用机制划分

• 市场分析、洞察与预测
• 蛋白质合成抑制剂
• 细胞壁合成抑制剂
• RNA合成抑制剂
• DNA合成抑制剂
• 其他的

第八章：全球抗生素抗药性市场：依分销管道划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第九章：全球抗生素抗药性市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十一章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Melinta Therapeutics
  • Basilea Pharmaceutica Ltd
  • Tetraphase Pharmaceuticals
  • Theravance Biopharma
  • Wockhardt
  • Paratek Pharmaceuticals Inc
  • Seres Therapeutics
  • Achaogen Inc
  • Entasis Therapeutics
  • AbbVie
  • Merck & Co. Inc

The Antibiotic Resistance Market size is expected to reach USD 17.27 Billion in 2034 from USD 10.37 Billion (2025) growing at a CAGR of 5.83% during 2026-2034.

The Global Antibiotic Resistance Market is gaining attention as antimicrobial resistance emerges as one of the most critical public health challenges worldwide. The overuse and misuse of antibiotics in human medicine and agriculture have accelerated the development of drug-resistant bacteria, making infections more difficult to treat. As healthcare systems struggle to combat resistant pathogens, the demand for innovative diagnostic tools, alternative therapies, and novel antimicrobial drugs is increasing significantly across global markets.

Key growth drivers include rising awareness about antimicrobial resistance, increasing government initiatives to control antibiotic misuse, and growing investments in research and development of new antibiotics. Healthcare organizations are also focusing on antimicrobial stewardship programs to promote responsible use of antibiotics. Additionally, advancements in rapid diagnostic technologies are helping clinicians identify resistant infections more effectively, enabling targeted treatment and reducing unnecessary antibiotic prescriptions.

The future outlook of the Global Antibiotic Resistance Market is shaped by collaborative global efforts among governments, pharmaceutical companies, and research institutions. Investments in biotechnology and innovative drug discovery platforms are expected to accelerate the development of next-generation antimicrobial treatments. Furthermore, international initiatives aimed at strengthening surveillance systems and improving infection control practices are likely to support market growth. As antimicrobial resistance continues to pose a global health threat, the market for solutions addressing this challenge is expected to expand steadily.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Disease

• cUTI (Complicated Urinary Tract Infections)
• CDI (Clostridioides difficile Infection)
• ABSSSI (Acute Bacterial Skin and Skin Structure Infections)
• HABP (Hospital-Acquired Bacterial Pneumonia)
• CABP (Community-Acquired Pneumonia)
• cIAI (Complicated Intra-Abdominal Infection)
• BSI (Bloodstream Infection)

By Pathogen

• E. Coli
• K. Pneumoniae
• P. Aeruginosa
• S. Aureus
• Baumannii
• S. Pneumoniae
• H. Influenzae
• Difficile
• E. Faecium

By Drug Class

• Oxazolidinones
• Lipoglycopeptides
• Tetracyclines
• Combination Therapies
• Cephalosporins
• Others

By Mechanism of Action

• Protein Synthesis Inhibitors
• Cell Wall Synthesis Inhibitors
• RNA Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Melinta Therapeutics, Basilea Pharmaceutica Ltd, Tetraphase Pharmaceuticals, Theravance Biopharma, Wockhardt, Paratek Pharmaceuticals Inc, Seres Therapeutics, Achaogen Inc, Entasis therapeutics, AbbVie, Merck Co Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTIBIOTIC RESISTANCE MARKET: BY DISEASE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Disease
• 4.2. cUTI (Complicated Urinary Tract Infections) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. CDI (Clostridioides difficile Infection) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. ABSSSI (Acute Bacterial Skin and Skin Structure Infections) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. HABP (Hospital-Acquired Bacterial Pneumonia) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. CABP (Community-Acquired Pneumonia) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. cIAI (Complicated Intra-Abdominal Infection) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. BSI (Bloodstream Infection) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTIBIOTIC RESISTANCE MARKET: BY PATHOGEN 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Pathogen
• 5.2. E. Coli Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. K. Pneumoniae Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. P. Aeruginosa Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. S. Aureus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Baumannii Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. S. Pneumoniae Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. H. Influenzae Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Difficile Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. E. Faecium Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTIBIOTIC RESISTANCE MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Drug Class
• 6.2. Oxazolidinones Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Lipoglycopeptides Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Tetracyclines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Combination Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Cephalosporins Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTIBIOTIC RESISTANCE MARKET: BY MECHANISM OF ACTION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Mechanism Of Action
• 7.2. Protein Synthesis Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Cell Wall Synthesis Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. RNA Synthesis Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. DNA Synthesis Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANTIBIOTIC RESISTANCE MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ANTIBIOTIC RESISTANCE MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Disease
  • 9.2.2 By Pathogen
  • 9.2.3 By Drug Class
  • 9.2.4 By Mechanism Of Action
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Disease
  • 9.3.2 By Pathogen
  • 9.3.3 By Drug Class
  • 9.3.4 By Mechanism Of Action
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Disease
  • 9.4.2 By Pathogen
  • 9.4.3 By Drug Class
  • 9.4.4 By Mechanism Of Action
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Disease
  • 9.5.2 By Pathogen
  • 9.5.3 By Drug Class
  • 9.5.4 By Mechanism Of Action
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Disease
  • 9.6.2 By Pathogen
  • 9.6.3 By Drug Class
  • 9.6.4 By Mechanism Of Action
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL ANTIBIOTIC RESISTANCE INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Melinta Therapeutics
  • 11.2.2 Basilea Pharmaceutica Ltd
  • 11.2.3 Tetraphase Pharmaceuticals
  • 11.2.4 Theravance Biopharma
  • 11.2.5 Wockhardt
  • 11.2.6 Paratek Pharmaceuticals Inc
  • 11.2.7 Seres Therapeutics
  • 11.2.8 Achaogen Inc
  • 11.2.9 Entasis Therapeutics
  • 11.2.10 AbbVie
  • 11.2.11 Merck & Co. Inc